CervoMed Inc. 8K

CervoMed received a UK ILAP Innovation Passport designation for its DLB drug candidate neflamapimod, enabling an accelerated and more coordinated development and access pathway.

CervoMed Inc. announced that its lead drug candidate neflamapimod has been granted an Innovation Passport designation under the UK Innovative Licensing and Access Pathway (ILAP) for the treatment of Dementia with Lewy Bodies, providing the company with early and coordinated guidance and enhanced support from the UK Medicines and Healthcare products Regulatory Agency, the National Health System, and health technology assessment bodies to help accelerate development, regulatory review, and potential patient access in the UK as it prepares for a planned Phase 3 trial.

Filing Facts

CIK

1053691

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-025509

Alert Tier

6